ebitda adj includ impair charg
valu usd unless otherwis note
rhetor question comment deal
view rais target price target multipl share
reflect increas visibl certainti deal close de-risk
invest thesi relat pbm rebat significantli higher
multipl compani sum part analysi
small slide time commun recent state
expect aet deal close earli push time
slightli versu late expect last earn
call expect deal close end octob deal typic
close end month believ indic high degre
confid part deal spread also indic
immin deal close tighter deal spread ci/esrx
forma model pro forma ep estim cvs/aet stand
ep estim share trade
pf ep estim estim
view valuat compel rel
price-to-earnings trade price-to-earnings may
minor divestitur requir doj approv model reflect
conserv estim oper profit attrit captur
expect divestitur
make public appear tout administr
goal lower drug price azar comment address reform
payment system light specif also continu
wait detail propos rule hh sent omb
see administr plan elimin rebat system
believ payment reform could requir legisl chang could
prove slow meet polit resist exampl text
requir drug compani disclos price ad pull
minibu govern fund bill make us question whether
administr either capabl stomach challeng
statu quo unless hh will make pbm fiduciari and/or
directli negoti drug price believ govern tool
effect chang without help support congress
maintain op rate rais pt maintain outperform rate
share rais price target impli upsid
current level price target base appli
multipl pro forma ep estim
move pro forma ep estim reflect increas visibl
certainti deal close multipl reflect weight sum
part multipl largest compon new compani
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
price target share base appli
multipl pro forma ep estim
multipl reflect weight sum part multipl
largest compon new compani note
sum part support target multipl
discount one turn reflect near
term execut risk relat deal
upsid scenario reflect pro forma earn
assum aet deal close upsid assum share
trade pro forma ep
downsid scenario unabl close aetna
acquisit amazon compani out-execut
compani lead potenti neg revis multipl
compress downsid scenario impli ep
estim ep estim
health provid wide array health care
servic
oper follow
segment pharmaci servic retail/long-term
benefit manag solut well specialti drug
manag retail long-term segment includ
sell prescript drug assort gener
administr servic
believ inflect point corpor
life cycl pursu strategi vertic
integr announc acquisit aetna
import macro trend healthcar move
away fee servic transact model toward
coordin value-bas care deliveri view
collect asset could better util
coordin ownership believ
steerag capabl combin pbm could
drive volum cvss segment offset
risk busi loss relat acquisit
increas competit core pharmaci pbm
increas price pressur commerci payer
well underli drug environ
risk large-custom exclus defect either
retail pbm segment
regulatori approv aetna deal
execut aetna merger synergi forecast
deal
prior adjust attrit corpor expens
capit market prior adjust attrit corpor expens
multipleweight front exhibit aet forma model
includ intracompani revenu increas aet pbmrevenu pbm attrit like conservativepf adj oper op attrition- margin lost synergies- none target full year forma compani disclosur debt paydown lower int tax new blend rate share share repo limit comp interest lower tax rate drive upsideaccret sheet short term debt- long term enterpris equiti valu increas could off-set debt declinenet rental total debt rental adj rental adj net oblig ttm adj term target low excess cash debt roll ec debt paydown first three yearscv ep ebitda healthaetnacombin healthcar technolog distribut
price target share base appli multipl pro forma
ep estim multipl reflect weight sum part multipl
largest compon new compani note sum part support
target multipl discount one turn reflect near term
execut risk relat deal price target support outperform rate
risk rate price target
share see sever downsid risk rate price target risk includ
increas price competit walgreen retail pharmaci space well
reimburs pressur wors expect third-parti payer
also risk see increas competit relat pbm network strategi
could reduc script volum risk obtain approv
otherwis complet announc acquisit aetna
pbm side busi risk includ could lose busi
see meaning reduct margin relat serv client risk includ
regular competit could lose market share either optum express script
prime aetna acquisit also present risk could disrupt client
health corp engag provis health care servic oper
follow segment pharmaci servic retail long term corpor
pharmaci servic segment offer pharmaci benefit manag solut retail
long term segment includ sell prescript drug assort gener
merchandis corpor segment involv provid manag administr
servic compani headquart woonsocket ri
million
revenu
depreci amort
loss earli extinguish debt
incom incom tax provis
incom continu oper
loss discontinu oper net tax
net loss attribut non-controlling interest
net incom attribut health
earn particip secur
incom common sharehold
adjust incom incom tax provis
adjust incom continu oper
net loss attribut non-controlling interest
adjust incom continu oper attribut
